Podcast 110: ARBs (and anti-hypertensives, generally) pose no measurable cancer risk, meta-analysis shows.

This week’s guest, Dr. Sripal Bangalore, finds no evidence that use of the standard anti-hypertensive drugs increases risks for cancer. His meta-analysis did find, however, an indication that ARBs and ACE inhibitors, when used in combination, increase risks modestly. Even with the short follow-up, Bangalore says clinicians should find reassurance in the results.

Listen in.

Interview-related links:

• Physician’s First Watch coverage of the Lancet Oncology meta-analysis
• Lancet Oncology abstract
• FDA MedWatch statement (July 2010) concerning ongoing investigation of ARBs and cancer risk
• First Watch coverage of earlier Lancet Oncology meta-analysis (June 2010) raising concerns

The post Podcast 110: ARBs (and anti-hypertensives, generally) pose no measurable cancer risk, meta-analysis shows. first appeared on Clinical Conversations.